VYEPTIHCP.COM: Keyword Density Checker

Total words: 2260 | 2-word phrases: 598 | 3-word phrases: 662 | 4-word phrases: 679

PAGE INFO

Title	Try to keep the title under 60 characters (70 characters) VYEPTI® (eptinezumab-jjmr) IV Infusion \| Powerful Migraine Prevention
Description	Try to keep the meta description between 50 - 160 characters (167 characters) VYEPTI is the first IV anti-CGRP infusion for migraine prevention. See VYEPTI clinical data, impact on patients’ lives, safety profile, cost and savings information.
Keywords	Meta keywords are not recommended anymore (204 characters) migraine prevention, IV anti-CGRP, migraine treatment, chronic migraine, episodic migraine, migraine medication, break free, vicious cycle of migraine, frequent migraine, severe migraine, acute medication
H1	No H1 tag on the page (0 characters)

ONE WORD PHRASES 321 Words

#	Keyword	Frequency	Density
1	and	36	11.21%
2	the	33	10.28%
3	vyepti	33	10.28%
4	of	24	7.48%
5	for	21	6.54%
6	in	17	5.30%
7	infusion	16	4.98%
8	information	15	4.67%
9	is	14	4.36%
10	reactions	14	4.36%

TWO WORD PHRASES 598 Words

#	Keyword	Frequency	Density
1	hypersensitivity reaction	10	1.67%
2	hypersensitivity reactions	8	1.34%
3	the preventive	6	1.00%
4	your patients	6	1.00%
5	in the	6	1.00%
6	prescribing information	6	1.00%
7	treatment of	6	1.00%
8	preventive treatment	6	1.00%
9	for the	6	1.00%
10	vyepti is	6	1.00%
11	of the	5	0.84%
12	of migraine	5	0.84%
13	is a	5	0.84%
14	real vyepti	5	0.84%
15	vyepti in	4	0.67%
16	adverse reactions	4	0.67%
17	información de	4	0.67%
18	patient information	4	0.67%
19	the postmarketing	4	0.67%
20	clinical trials	4	0.67%

THREE WORD PHRASES 662 Words

#	Keyword	Frequency	Density
1	for the preventive	6	0.91%
2	preventive treatment of	6	0.91%
3	the preventive treatment	6	0.91%
4	of migraine in	4	0.60%
5	indicated for the	4	0.60%
6	is indicated for	4	0.60%
7	vyepti is indicated	4	0.60%
8	treatment of migraine	4	0.60%
9	in the postmarketing	4	0.60%
10	real vyepti experience	4	0.60%
11	please see the	3	0.45%
12	see the full	3	0.45%
13	and at least	2	0.30%
14	≥2 and at	2	0.30%
15	is contraindicated in	2	0.30%
16	contraindicated in patients	2	0.30%
17	in patients with	2	0.30%
18	at least 2	2	0.30%
19	information and indication	2	0.30%
20	patients with serious	2	0.30%
21	vyepti is contraindicated	2	0.30%
22	this website is	2	0.30%
23	important safety information	2	0.30%
24	with serious hypersensitivity	2	0.30%
25	serious hypersensitivity to	2	0.30%
26	reactions ≥2 and	2	0.30%
27	adverse reactions ≥2	2	0.30%
28	eptinezumabjjmr or to	2	0.30%
29	or to any	2	0.30%
30	to any of	2	0.30%

FOUR WORD PHRASES 679 Words

#	Keyword	Frequency	Density
1	the preventive treatment of	6	0.88%
2	for the preventive treatment	6	0.88%
3	treatment of migraine in	4	0.59%
4	vyepti is indicated for	4	0.59%
5	preventive treatment of migraine	4	0.59%
6	indicated for the preventive	4	0.59%
7	is indicated for the	4	0.59%
8	please see the full	3	0.44%
9	this website is intended	2	0.29%
10	consider discontinuing vyepti and	2	0.29%
11	occurs consider discontinuing vyepti	2	0.29%
12	reaction occurs consider discontinuing	2	0.29%
13	hypersensitivity reaction occurs consider	2	0.29%
14	postmarketing setting if a	2	0.29%
15	the postmarketing setting if	2	0.29%
16	most common adverse reactions	2	0.29%
17	reported in the postmarketing	2	0.29%
18	been reported in the	2	0.29%
19	have been reported in	2	0.29%
20	anaphylaxis have been reported	2	0.29%
21	may occur cases of	2	0.29%
22	reactions may occur cases	2	0.29%
23	hypersensitivity reactions may occur	2	0.29%
24	serious hypersensitivity reactions may	2	0.29%
25	treatment serious hypersensitivity reactions	2	0.29%
26	to discontinuation or required	2	0.29%
27	the most common adverse	2	0.29%
28	and at least 2	2	0.29%
29	common adverse reactions ≥2	2	0.29%
30	clinical trials for the	2	0.29%
31	see the full prescribing	2	0.29%
32	information please see the	2	0.29%
33	more information please see	2	0.29%
34	for more information please	2	0.29%
35	were nasopharyngitis and hypersensitivity	2	0.29%
36	migraine were nasopharyngitis and	2	0.29%
37	trials for the preventive	2	0.29%
38	the clinical trials for	2	0.29%
39	adverse reactions ≥2 and	2	0.29%
40	in the clinical trials	2	0.29%

EXTERNAL LINKS

#	URL	Whois	Check
1	https://www.vyepti.com	Whois	vyepti.com
2	https://www.vyepti.com	Whois	vyepti.com
3	https://www.vyepti.com	Whois	vyepti.com
4	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_en.pdf	Whois	lundbeck.com
5	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_en.pdf	Whois	lundbeck.com
6	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_es.pdf	Whois	lundbeck.com
7	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_es.pdf	Whois	lundbeck.com
8	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_en.pdf	Whois	lundbeck.com
9	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_en.pdf	Whois	lundbeck.com
10	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_es.pdf	Whois	lundbeck.com
11	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_es.pdf	Whois	lundbeck.com
12	https://portal.trialcard.com/lundbeck/vyepti	Whois	trialcard.com
13	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_en.pdf	Whois	lundbeck.com
14	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_en.pdf	Whois	lundbeck.com
15	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_en.pdf	Whois	lundbeck.com
16	https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_en.pdf	Whois	lundbeck.com
17	https://www.lundbeck.com/us/terms-of-use	Whois	lundbeck.com
18	https://www.lundbeck.com/us/privacy-policy	Whois	lundbeck.com
19	https://www.lundbeck.com/us/contact	Whois	lundbeck.com